VanEck Associates
FOLD

VanEck Associates’s Amicus Therapeutics FOLD Stock Holding History

VanEck Associates’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,573
Closed -$182K – 1385
2026
Q1 		$182K Buy
12,573
+447
+4% +$6.41K ﹤0.01% 1270
2025
Q4 		$173K Buy
12,126
+6,488
+115% +$63.7K ﹤0.01% 1294
2025
Q3 		$44K Buy
5,638
+1,466
+35% +$10.4K ﹤0.01% 1348
2025
Q2 		$24K Hold
4,172
– – ﹤0.01% 1352
2025
Q1 		$34K Hold
4,172
– – ﹤0.01% 1316
2024
Q4 		$39K Buy
4,172
+715
+21% +$7.43K ﹤0.01% 1306
2024
Q3 		$39K Sell
3,457
-1,107
-24% -$12.1K ﹤0.01% 1283
2024
Q2 		$45K Hold
4,564
– – ﹤0.01% 1294
2024
Q1 		$54K Sell
4,564
-93
-2% -$1.19K ﹤0.01% 1279
2023
Q4 		$66K Buy
4,657
+873
+23% +$9.91K ﹤0.01% 1268
2023
Q3 		$46K Buy
3,784
+161
+4% +$2.08K ﹤0.01% 1289
2023
Q2 		$46K Buy
3,623
+312
+9% +$3.7K ﹤0.01% 1304
2023
Q1 		$37K Buy
3,311
+323
+11% +$3.98K ﹤0.01% 1324
2022
Q4 		$36K Buy
2,988
+981
+49% +$11K ﹤0.01% 1331
2022
Q3 		$21K Buy
+2,007
New +$22.4K ﹤0.01% 1316

Other funds holding FOLD

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

VanEck Associates's FOLD Position: Q2 2026 in Review

VanEck Associates sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 12,573 shares — an estimated $182K sold.

VanEck Associates first reported a position in FOLD in Q3 2022 and held it in 15 quarters. The position peaked at $182K in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

  • VanEck Associates reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • VanEck Associates sold 12,573 Amicus Therapeutics shares in Q2 2026, an estimated $182K.
  • VanEck Associates first reported a position in Amicus Therapeutics in Q3 2022 and held it in 15 quarters.
  • VanEck Associates's Amicus Therapeutics position peaked at $182K in Q1 2026.
  • 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.